首页 > 抗体蛋白 > 抗体
PE/Cyanine5 anti-mouse CD8a Antibody
产品名称:
PE/Cyanine5 anti-mouse CD8a Antibody
产品类别:
抗体
产品编号:
100709
产品应用:
100709
[价格]
规格 价格 库存
25µg ¥ 924 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.04 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Additional Product Notes
BioLegend is in the process of converting the name PE/Cy5 to PE/Cyanine5. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine5 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  30. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  2. Hofmann I, et al. 2022. J Pharmacol Exp Ther. Online ahead of print. PubMed
  3. Sch?nberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  4. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  5. Kurosawa M, et al. 2021. Int J Mol Sci. 22:. PubMed
  6. Karagiannidis I, et al. 2020. Front Immunol. 11:1885. PubMed
  7. Stolp B, et al. 2022. Cell Rep. 38:110387. PubMed
  8. Ihara S, et al. 2022. PLoS Negl Trop Dis. 16:e0010323. PubMed
  9. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  10. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  11. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  12. Sharma PK, et al. 2018. Cancer Gene Ther. 25:27. PubMed
  13. Pereira JL, et al. 2021. Transl Oncol. 14:101125. PubMed
  14. Pein M, et al. 2020. Nat Commun. 11:1494. PubMed
  15. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  16. Gungor B, et al. 2014. Sci Transl Med. 6:235. PubMed
  17. Di Genua C, et al. 2020. Cancer Cell. 37(5):690-704.e8.. PubMed
  18. Cervera–Carrascon V, et al. 2020. Oncoimmunology. 9:1761229. PubMed
  19. Wachsmuth LP, et al. 2020. Biol Blood Marrow Transplant. 26:230. PubMed
  20. Garland KM, et al. 2021. Front Immunol. 12:753472. PubMed
  21. Yankova E, et al. 2021. Nature. 593:597. PubMed
  22. Booth CAG, et al. 2018. Cancer Cell. 33:274. PubMed
  23. Ma P, et al. 2014. Diabetes. 63:3458. PubMed
  24. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
  25. Sim S, et al. 2016. PLoS One. 11: 0152485. PubMed
  26. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  27. Yang R, et al. 2022. J Adv Res. 35:259. PubMed
  28. Sun L, et al. 2015. Sci Rep. 5: 14871. PubMed
  29. XS R, et al. 2015. Diabetes. 64 90. PubMed
  30. Naik A, et al. 2015. J Immunol. 194:790. PubMed
  31. Tomay F, et al. 2019. J Transl Med. 17:237. PubMed
  32. Edwards-Hicks J, et al. 2020. Metabolites. 11:. PubMed
  33. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  34. Todd D, et al. 2009. J Exp Med. 206:2151. PubMed
  35. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  36. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
  37. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  38. Tzelepis K, et al. 2018. Nat Commun. 9:5378. PubMed
  39. Di Genua C, et al. 2019. Haematologica. 104:2215. PubMed
  40. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  41. Lo W, et al. 2014. Elife. 14:1457. PubMed
  42. Bryan Hart, Sunhee Lee 2016. PLoS Negl Trop Dis. 10:e0005229. PubMed
  43. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  44. Chavez JS, et al. 2022. Cells. 11:. PubMed
  45. Hart B, et al. 2015. PLoS Negl Trop Dis. 9: 0004046. PubMed
  46. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  47. Gozdecka M, et al. 2018. Nat Genet. 50:883. PubMed
  48. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
RRID
AB_312748 (BioLegend Cat. No. 100709) AB_312749 (BioLegend Cat. No. 100710)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8a on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线